A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910